行情

ADMA

ADMA

Adma生物制品
NASDAQ

实时行情|Nasdaq Last Sale

3.090
+0.500
+19.31%
盘后: 3.030 -0.06 -1.94% 19:40 04/03 EDT
开盘
2.580
昨收
2.590
最高
3.120
最低
2.500
成交量
463.52万
成交额
--
52周最高
5.48
52周最低
1.450
市值
2.67亿
市盈率(TTM)
-3.4117
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ADMA价格均价为11.00,最高价位15.00,最低价为6.00。

EPS

ADMA 新闻

更多
  • 迪拜将人员流动限制措施扩大至24小时限制
  • 新浪美股 · 1小时前
  • 特朗普称将申请更多中小企业纾困资金
  • 央视 · 2小时前
  • 美加联合施压促减产 考虑对沙特和俄罗斯石油征税
  • 新浪美股 · 2小时前
  • 瑞幸财务造假?创始人割韭菜?20分钟看懂浑水89页做空报告
  • 新浪财经-自媒体综合 · 3小时前

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

ADMA 简况

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
展开

微牛提供ADMA Biologics Inc(NASDAQ-ADMA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ADMA股票新闻,以帮助您做出投资决策。